Sponsored by Merck & Co.

The FDA has received 700 reports of suicide or suicidal ideation among people who took Propecia following its decision 10 years ago to not issue a warning to consumers.

Merck reported worldwide sales of $10.9 billion, down 8% for the second quarter of 2020.

Maksym Nienadov, the owner of Ukrainian-based company Healthy Nation, and his employee, 33-year-old Volodymyr Nikolaienko, pleaded guilty to trafficking in counterfeit drugs.

The Food and Drug Administration designated Koselugo as an orphan drug to treat neurofibromatosis type 1, which affects 3,000 to 4,000 individuals.

Merck & Co. is cutting 500 jobs across the U.S. as it looks to make "several changes" to its U.S. commercial organization.

The jury said Gilead has "willfully" infringed on Merck's patent.

Developing a vaccine against the mosquito-borne virus could take years, researchers have said.

Analysts predict that Uptravi, a new drug from Swiss company Actelion, could hit annual sales of $1 billion or more in the U.S.

The pharmaceutical giants are among 40 Standard & Poor's 500 companies reporting quarterly results Tuesday.

The human safety trial ended early after some patients receiving the experimental VSV-ZEBOV Ebola vaccine complained of joint pain.

The deal would help expand its hold in the antibiotics sector and get access to Cubist's medicines, mostly used in hospitals.

The U.S. pharmaceutical company is divesting assets and investing in research for new products like insomnia drug Belsomra.

Merck, which has been hit by several drug development failures, wants its own pharmaceuticals business to remain a medium-sized entity.

The FDA-approved Keytruda is the first in a new range of drugs that could revolutionize the treatment of some cancers.

More than 150 million people worldwide and three million Americans suffer from hepatitis C, which does not have a vaccine till date.

Sales of Sovaldi, which cures hepatitis C in 12 weeks, hit a record-breaking $2.3 billion within a few weeks.

The definitive agreement comes as pharmaceutical companies struggle against the growing market share of generic medicines.

Merck's latest layoffs are coming from both marketing and research and development.

Tyson Foods, the largest U.S. meat processor, suspended purchases of cattle fed with Zilmax, claiming the growth enhancer caused problems.

Drugmaker Merck will discuss new drugs and Q1 sales trends as it braces for new generic competition.

Patent expirations for lucrative blockbuster drugs eroded fourth-quarter sales for top drugmakers.

The top after-market NASDAQ gainers Monday were Urban Outfitters Inc, Merrimack Pharmaceuticals Inc, InterMune Inc, Ariad Pharmaceuticals Inc and Albany Molecular Research Inc. The top after-market NASDAQ losers Monday were Alnylam Pharmaceuticals Inc, JA Solar Holdings Company, MAKO Surgical and Mobile Mini Inc.

The pharmaceutical industry is grappling with diminishing R&D productivity -- exemplified by a drop in revenue per new drug approval.

Pharmaceutical companies are still struggling with a steep "patent cliff," as multiple blockbusters lose their patent protections.

Merck & Co., Inc. (NYSE:MRK), the Whitehouse Station, N.J.-based pharmaceutical giant, is borrowing about $2.5 billion to service corporate and contribute to its pension fund.

Researchers from the University of North Carolina at Chapel Hill in collaboration with scientists from the Harvard School of Public Health, National Cancer Institute, Merck and the University of California have identified a drug employed in treating certain types of lymphoma that help dislodge a hidden virus in patients receiving treatment for HIV.

Based on analyst estimates, Merck & Co. will report earnings of $1.01 a share on sales of about $12.16 billion -- an increase of 0.1 percent from the year-earlier quarter. The company posts its second-quarter earnings on Friday, before the opening bell.

American International Group, DryShips, Merck & Co, Complete Genomics, SAP AG, Deutsche Bank and Cognizant Technology Solutions Corp. are among the companies whose shares are moving in pre-market trading Thursday.

Stocks rose modestly on Friday, putting equities on track for a fourth day of gains as more strong earnings partially offset a weaker-than-expected reading on economic growth.